NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
Clinical Trials
10 trialsNCT05553522 2025-12-31
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Baptist Health South Florida
Phase 1 Terminated
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04965064 2025-12-15
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
University of Rochester
Phase 2 Recruiting
NCT05535413 2025-04-25
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Hunan Cancer Hospital
Phase 1/2 Recruiting
NCT03213002 2025-04-09
CAPTEM
Northwell Health
Phase 1/2 Recruiting
NCT00570908 2014-09-18
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Baylor Breast Care Center
Phase 2 Terminated
NCT00967031 2013-01-18
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
UNICANCER
Phase 2 Completed
NCT00227656 2012-12-11
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00504660 2012-01-11
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
Phase 2 Completed